HC Wainwright Reaffirms “Buy” Rating for Inventiva (NASDAQ:IVA)

Inventiva (NASDAQ:IVA)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $13.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 342.18% from the company’s current price.

Separately, TD Cowen started coverage on Inventiva in a research report on Friday, February 21st. They issued a “buy” rating and a $10.00 price objective for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.60.

Inventiva Price Performance

NASDAQ IVA opened at $2.94 on Friday. Inventiva has a 1-year low of $1.53 and a 1-year high of $3.98. The stock has a 50-day moving average of $2.69 and a 200-day moving average of $2.48.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.